Global Patent Index - EP 2614828 A4

EP 2614828 A4 20140326 - LOW-MODIFICATION BIOCOMPATIBLE HIGH POLYMER SULFHYDRYL-MODIFIED DERIVATIVES, CROSS-LINKED MATERIAL THEREOF, AND USES OF SAID MATERIAL

Title (en)

LOW-MODIFICATION BIOCOMPATIBLE HIGH POLYMER SULFHYDRYL-MODIFIED DERIVATIVES, CROSS-LINKED MATERIAL THEREOF, AND USES OF SAID MATERIAL

Title (de)

GERING VERÄNDERTE UND BIOKOMPATIBLE SULFHYDRYL-MODIFIZIERTE DERIVATE MIT HOHEM POLYMERANTEIL, VERNETZTES MATERIAL DARAUS UND ANWENDUNGEN DIESES MATERIALS

Title (fr)

DÉRIVÉS MODIFIÉS PAR SULFHYDRYLE DE POLYMÈRE HAUTEMENT BIOCOMPATIBLE À LÉGÈRE MODIFICATION, MATÉRIAU RÉTICULÉ DE CES DÉRIVÉS ET UTILISATION DE CE MATÉRIAU

Publication

EP 2614828 A4 20140326 (EN)

Application

EP 11823038 A 20110804

Priority

  • CN 201010277374 A 20100909
  • CN 2011077985 W 20110804

Abstract (en)

[origin: EP2614828A2] Disclosed are low-modification biocompatible high polymer sulfhydryl-modified derivatives. The derivatives have a very low degree of sulfhydryl modification, and maintain to the greatest extent possible the initial structure, physiological function, and biocompatibility of the biocompatible high polymer. At the same time, the sulfhydryl introduced effectively carries out chemical cross-linking so as to produce a biocompatible high polymer cross-linked material having a low degree of cross-linking. Also disclosed is a type of disulfide cross-linked biocompatible high polymer cross-linked material. This cross-linked material has a low degree of cross-linking and not only maintains to the greatest extent possible the initial structure, physiological functions, and biocompatibility of the biocompatible high polymer, but also delays metabolization of the biocompatible high polymer in the body and reduces solubility. This satisfies a variety of needs in terms of clinical application. The present invention relates also to the use of disulfide cross-linked biocompatible high polymer cross-linked material in medical science and pharmacology.

IPC 8 full level

A61K 31/573 (2006.01); C08B 37/00 (2006.01); C08J 3/075 (2006.01)

CPC (source: EP US)

A61K 9/0024 (2013.01 - US); A61K 9/06 (2013.01 - US); A61K 31/573 (2013.01 - EP US); A61K 31/728 (2013.01 - US); A61K 31/737 (2013.01 - US); A61K 31/738 (2013.01 - EP US); A61K 45/06 (2013.01 - US); A61L 31/04 (2013.01 - EP US); A61P 19/00 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 41/00 (2017.12 - EP); C08B 37/0069 (2013.01 - EP US); C08B 37/0072 (2013.01 - EP US); C08F 8/34 (2013.01 - US); C08J 3/075 (2013.01 - EP US); C08L 101/02 (2013.01 - EP US); C08J 2301/00 (2013.01 - EP US)

Citation (search report)

  • [X] WO 2009132226 A1 20091029 - MEDTRONIC INC [US], et al
  • [X] KAFEDJIISKI KRUM ET AL: "Evaluation of in vitro enzymatic degradation of various thiomers and cross-linked thiomers.", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY FEB 2007, vol. 33, no. 2, February 2007 (2007-02-01), pages 199 - 208, XP002719830, ISSN: 0363-9045
  • [X] HAHN SEI KWANG ET AL: "Injectable hyaluronic acid microhydrogels for controlled release formulation of erythropoietin", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 80A, no. 4, March 2007 (2007-03-01), pages 916 - 924, XP002719831
  • [Y] XIAO ZHENG SHU ET AL: "Disulfide Cross-Linked Hyaluronan Hydrogels", BIOMACROMOLECULES, vol. 3, no. 6, 1 November 2002 (2002-11-01), pages 1304 - 1311, XP055005444, ISSN: 1525-7797, DOI: 10.1021/bm025603c
  • [Y] SHU X Z ET AL: "Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 24, no. 21, 1 September 2003 (2003-09-01), pages 3825 - 3834, XP004431163, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(03)00267-9
  • [Y] PROCTOR MATTHEW ET AL: "Composition of hyaluronan affects wound healing in the rabbit maxillary sinus.", AMERICAN JOURNAL OF RHINOLOGY 2006 MAR-APR, vol. 20, no. 2, March 2006 (2006-03-01), pages 206 - 211, XP009175896, ISSN: 1050-6586
  • [Y] A BERNKOPSCHNURCH: "Thiomers: A new generation of mucoadhesive polymers", ADVANCED DRUG DELIVERY REVIEWS, vol. 57, no. 11, 3 November 2005 (2005-11-03), pages 1569 - 1582, XP055022283, ISSN: 0169-409X, DOI: 10.1016/j.addr.2005.07.002
  • See references of WO 2012031515A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 2614828 A2 20130717; EP 2614828 A4 20140326; EP 2614828 B1 20161019; AU 2011301069 A1 20130411; AU 2011301069 B2 20160310; CA 2810590 A1 20120315; CA 2810590 C 20170822; CN 102399295 A 20120404; CN 102399295 B 20131106; ES 2601812 T3 20170216; JP 2013537050 A 20130930; JP 6063867 B2 20170118; US 10064889 B2 20180904; US 2013338099 A1 20131219; US 2016263147 A1 20160915; US 9446067 B2 20160920; WO 2012031515 A2 20120315; WO 2012031515 A3 20130502

DOCDB simple family (application)

EP 11823038 A 20110804; AU 2011301069 A 20110804; CA 2810590 A 20110804; CN 201010277374 A 20100909; CN 2011077985 W 20110804; ES 11823038 T 20110804; JP 2013527457 A 20110804; US 201113821666 A 20110804; US 201615078389 A 20160323